VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24105GJ1982PLC005057

Date: 07th August, 2026

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai — 400001
Maharashtra, India

BSE Scrip Code- 530057 **ISIN: INE984E01035**

Subject: <u>Outcome of Board of Directors Meeting of Vivanza Biosciences Limited ("the Company")</u>

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. Friday, 07th August, 2026, at the Registered Office of the Company, has inter alia considered and approved the following businesses:

1. Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, together with the Limited Review Report (Annexure –A).

2. The Board took note of the disclosure of interest received from the Directors pursuant to Section 184 of the Companies Act, 2013 and the intimation of disqualification under Section 164 of the Companies Act, 2013.

3. The Board took note of the declarations received from the Independent Directors confirming that they meet the criteria of independence as prescribed under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of Board of Directors of the Company commenced at 12:45 P.M. and concluded at 13:00 P.M.

You are requested to kindly take the same on record and acknowledge.
Thanking You.

For, Vivanza Biosciences Limited

JAYENDRA AMICHAND MEHTA
Digitally signed by JAYENDRA AMICHAND MEHTA
Date: 2026.08.07 13:05:16 +05'30'

____

JAYENDRA MEHTA
MANAGING DIRECTOR
DIN: 08210602
Encl: As above

SHIVAM SONI & CO.
Chartered Accountants
Address : 802, Swati Clover, Nr. Shilaj Circle, Thaltej - Bopal Road, Ahmedabad - 380058
Phone : +91 94095 19080 E-mail : ca.shivam94@gmail.com

Limited review report on the Un-audited Standalone Financial Results for the quarter ended 30th June 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
Vivanza Biosciences Limited
Ahmedabad

We have reviewed the accompanying statement of Un-audited Standalone Financial Results of Vivanza Biosciences Limited ("the Company") for the quarter ended 30th June, 2026, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

SHIVAM SONI & CO. FRN No. 152477W AHMEDABAD CHARTERED ACCOUNTANTS

Shivam

CA Shivam Soni
Partner
Membership No. : 178351
UDIN : 26178351SGRLFD8547

Date : 07/08/2026
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
CIN : L24110GJ1982PLC005057
Ph.no.: 079-26870952/54 Email Id: info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026.

(Rs. in Lacs except per share data)

	Particulars	Quarter Ended			Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Income from Operations**				
	(a) Revenue from operations	914.09	574.60	782.06	11223.10
	(b) Other Income	37.28	0.77	1.74	10.94
	Total Income	**951.37**	**575.37**	**783.81**	**11234.04**
2	Expenses				
	(a) Cost of Materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	932.73	533.56	770.95	11,207.08
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	(24.83)	42.38	(15.63)	(110.25)
	(d) Employee benefits expense	9.56	3.84	9.22	33.08
	(e) Finance Cost	10.62	6.58	7.66	27.92
	(f) Depreciation and amortisation expense	0.54	1.10	0.35	2.16
	(g) Other expenses	4.67	0.22	9.40	22.27
	Total Expenses	**933.29**	**587.69**	**781.95**	**11182.25**
3	**Profit/(loss) before exceptional items and tax (1-2)**	**18.08**	**-12.32**	**1.86**	**51.79**
4	Exceptional Items	0.00	0.00	0.00	0.00
5	**Profit/(Loss) before tax (3-4)**	**18.08**	**-12.32**	**1.86**	**51.79**
6	**Tax Expense**				
	(a) Current tax	3.55	14.20	0.00	14.20
	(b) Deferred tax	0.02	0.09	0.00	0.09
	Total Tax Expenses	**3.57**	**14.29**	**0.00**	**14.29**
7	**Profit / (Loss) for the period from continuing oprations (5-6)**	**14.51**	**-26.61**	**1.86**	**37.50**
8	**Profit (Loss) from discontinuing oprations**	0.00	0.00	0.00	0.00
9	**Tax Expense of discontinuing oprations**	0.00	0.00	0.00	0.00
10	**Profit (Loss) from discontinuing oprations (after tax)(8-9)**	**0.00**	**0.00**	**0.00**	**0.00**
11	**Other Comprehensive Income**				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	Other Comprehensive Income for the period	**0.00**	**0.00**	**0.00**	**0.00**
12	**Total Comprehensive Income for the period**	**14.51**	**-26.61**	**1.86**	**37.50**
13	Paid-up equity share capital (Face value of Rs. 1/- each)	400	400	400	400
14	Other Equity	-	-	-	71.53
15	**Earnings Per Share (before extraordinary items) (not annualised):**				
	(a) Basic	0.04	-0.07	0.00	0.09
	(b) Diluted	0.04	-0.07	0.00	0.09
16	**Earnings Per Share (after extraordinary items) (not annualised):**				
	(a) Basic	0.04	-0.07	0.00	0.09
	(b) Diluted	0.04	-0.07	0.00	0.09

Notes:

1. The Above Standalone Unaudited Financial Results Have Been Reviewed By The Audit Committee And Approved By The Board Of Directors In Their Meeting Held On August 7,2026. The Limited Review Under Regulation 33 Of The Sebi (Listing Obligations And Disclosure Requirements) Regulations, 2015 Has Been Carried Out By The Statutory Auditors. The Limited Review Report Does Not Contain Any Observation Which Could Have An Impact On The Results For The Quarter Ended June 30, 2026.

2. The Company Adopted The Indian Accounting Standards ('Ind As') Effective 1St April, 2017 (Transition Date 1St April, 2016). The Financial Results Have Been Prepared In Acccordance With Ind As As Prescribed Under Section 133 Of The Companies Act, 2013 Read With The Relevant Rules Issued There Under.

3. The Company operates in 3 segments i.e.Pharmaceuticals, Agro And Film related activities

For, VIVANZA BIOSCIENCES LIMITED

VIVANZA BIOSCIENCES LIMITED AHMEDABAD

JAYENDRA MEHTA
Managing Director
DIN: 08210602

Date : 07-08-2026
Place : Ahmedabad

SHIVAM SONI & CO.
Chartered Accountants
Address : 802, Swati Clover, Nr. Shilaj Circle, Thaltej - Bopal Road, Ahmedabad - 380058
Phone : +91 94095 19080 E-mail : ca.shivam94@gmail.com

Limited review report on the Un-audited Consolidated Financial Results for the quarter ended 30th June 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
M/s Vivanza Biosciences Limited

We have reviewed the accompanying statement of Unaudited Consolidated Financial results of M/s Vivanza Biosciences Limited ("the Company") and its subsidiary (the Parent and its Subsidiary together referred to as "the Group"), for the quarter ended 30th June,2026, ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 , as amended.

This statement is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the consolidated financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statements includes the results of following entity ("the Subsidiary"): Vivanza Lifesciencies Private Limited.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules,2015 as specified in Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SHIVAM SONI & CO.
FRN No. 152477W
AHMEDABAD
CHARTERED ACCOUNTANTS

We did not review the financial results of subsidiary included in the consolidated unaudited financial results. These interim financial statement of the subsidiary have been reviewed by other auditor whose report has been furnished to us by the management and our conclusion on the statement, so far as it relates to amounts and disclosures included in respect of this subsidiary is based solely on the report of the auditor of the company and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the matter.

For SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Shivam

CA Shivam Soni
Partner
Membership No. : 178351
UDIN : 26178351RNRLNN2473

Date : 07/08/2026
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Ph.no.: 079-26870952/54 Email Id: info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026.

(Rs. in Lacs except per share data)

	Particulars	Quarter Ended			Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Income from Operations**				
	(a) Revenue from operations	928.97	636.29	893.92	11591.06
	(b) Other Income	37.28	0.86	1.74	11.15
	Total Income	**966.25**	**637.15**	**895.66**	**11602.21**
2	Expenses				
	(a) Cost of Materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	947.31	595.93	961.25	11571.38
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	(24.83)	56.01	(105.50)	(128.77)
	(d) Employee benefits expense	9.56	6.74	13.64	49.24
	(e) Finance Cost	10.62	6.58	7.66	27.92
	(f) Depreciation and amortisation expense	0.54	1.10	0.35	2.16
	(g) Other expenses	4.81	0.93	9.57	25.91
	Total Expenses	**948.01**	**667.30**	**886.96**	**11547.84**
3	**Profit/(loss) before exceptional items and tax** (1-2)	**18.24**	**-30.15**	**8.70**	**54.37**
4	Exceptional Items	0.00	0.00	0.00	0.00
5	**Profit/(Loss) before tax** (3-4)	**18.24**	**-30.15**	**8.70**	**54.37**
6	**Tax Expense**				
	(a) Current tax	3.55	14.85	0.00	14.85
	(b) Deferred tax	0.02	0.09	0.00	0.09
	Total Tax Expenses	**3.57**	**14.93**	**0.00**	**14.93**
7	**Profit / (Loss) for the period from continuing oprations** (5-6)	**14.67**	**-45.08**	**8.70**	**39.44**
8	**Profit (Loss) from discontinuing oprations**	0.00	0.00	0.00	0.00
9	**Tax Expense of discontinuing oprations**	0.00	0.00	0.00	0.00
10	**Profit (Loss) from discontinuing oprations (after tax)**(8-9)	**0.00**	**0.00**	**0.00**	**0.00**
11	Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00
12	Minority Interest *	0.00	0.00	0.00	0.00
13	**Other Comprehensive Income**				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	Other Comprehensive Income for the period	**0.00**	**0.00**	**0.00**	**0.00**
14	**Total Comprehensive Income for the period**	**14.67**	**-45.08**	**8.70**	**39.44**
15	**Total Comprehensive Income attributable to :**				
	Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00
	Minority Interest *	0.00	0.00	0.00	0.00
16	Paid-up equity share capital (Face value of Rs.1/- each)	400	400	400	400
17	Other Equity	-	-	-	35.85
18	**Earnings Per Share (before extraordinary items) (not annualised):**				
	(a) Basic	0.04	-0.11	0.02	0.10
	(b) Diluted	0.04	-0.11	0.02	0.10
19	**Earnings Per Share (after extraordinary items) (not annualised):**				
	(a) Basic	0.04	-0.11	0.02	0.10
	(b) Diluted	0.04	-0.11	0.02	0.10

Notes:

1. The Above Audited Consolidated Financial Results Have Been Reviewed By The Audit Committee And Approved By The Board Of Directors In Their Meeting Held On August 7,2026. The Audit Under Regulation 33 Of The Sebi (Listing Obligations And Disclosure Requirements) Regulations, 2015 Has Been Carried Out By The Statutory Auditors. The Audit Report Does Not Contain Any Observation Which Could Have An Impact On The Results For The Quarter/Year Ended June 30, 2026.

2. The Company Adopted The Indian Accounting Standards ('Ind As') Effective 1St April, 2017 (Transition Date 1St April, 2016). The Financial Results Have Been Prepared In Acccordance With Ind As As Prescribed Under Section 133 Of The Companies Act, 2013 Read With The Relevant Rules Issued There Under.

3. The Company operates in 3 segments i.e.Pharmaceuticals, Agro And Film related activities

For, VIVANZA BIOSCIENCES LIMITED

VIVANZA BIOSCIENCES LIMITED AHMEDABAD

JAYENDRA MEHTA
Managing Director
DIN: 08210602

Date : 07/08/2026
Place : Ahmedabad